News & Resources

Email Alerts

Email Address *
Mailing Lists *

Opexa Therapeutics Announces Analyst and Investor Event


THE WOODLANDS, Texas--(BUSINESS WIRE)-- Opexa Therapeutics, Inc. (NASDAQ: OPXA), a biopharmaceutical company developing personalized immunotherapies for autoimmune disorders, including multiple sclerosis (MS) and Neuromyelitis Optica (NMO), today announced that it will hold an Analyst and Investor Event in New York City, New York on Thursday, October 9, 2021.

Members of Opexa’s senior management team will provide an R&D update and review of the Company’s Abili-T clinical trial for Secondary Progressive Multiple Sclerosis and the development program for Neuromyelitis Optica.

The Analyst and Investor Event will take place from 8:00 a.m. to 9:15 a.m. Eastern Time at the New York Hilton Midtown, Madison Room (2nd floor). If you would like to attend the event, please confirm your attendance by e-mail to or via telephone at 281.775.0600.

A live webcast of the event will start at 8:15 a.m. and may be accessed on the Investor Relations section of the Company’s website, An archived version of the webcast will be available for 90 days after the event on the Company’s website.

About Opexa

Opexa is a biopharmaceutical company developing personalized immunotherapies with the potential to treat major illnesses, including multiple sclerosis (MS) as well as other autoimmune diseases such as neuromyelitis optica (NMO). These therapies are based on Opexa’s proprietary T-cell technology. The Company’s leading therapy candidate, Tcelna®, is a personalized T-cell immunotherapy that is in a Phase IIb clinical development program (the Abili-T trial) for the treatment of Secondary Progressive MS. Tcelna is derived from T-cells isolated from the patient’s peripheral blood, expanded ex vivo, and reintroduced into the patients via subcutaneous injections. This process triggers a potent immune response against specific subsets of autoreactive T-cells known to attack myelin. Opexa’s mission is to lead the field of Precision Immunotherapy® by aligning the interests of patients, employees and shareholders.

For more information visit the Opexa Therapeutics website at

Source: Opexa Therapeutics, Inc.

Opexa Therapeutics, Inc.

Karthik Radhakrishnan, 281-775-0600

Chief Financial Officer